| Literature DB >> 33987092 |
Francesca Piludu1, Simona Marzi2, Marco Ravanelli3, Raul Pellini4, Renato Covello5, Irene Terrenato6, Davide Farina3, Riccardo Campora3, Valentina Ferrazzoli7, Antonello Vidiri1.
Abstract
BACKGROUND: The differentiation between benign and malignant parotid lesions is crucial to defining the treatment plan, which highly depends on the tumor histology. We aimed to evaluate the role of MRI-based radiomics using both T2-weighted (T2-w) images and Apparent Diffusion Coefficient (ADC) maps in the differentiation of parotid lesions, in order to develop predictive models with an external validation cohort.Entities:
Keywords: DWI; MRI; head and neck (H&N) cancer; radiomics; salivary gland (SG) tumors
Year: 2021 PMID: 33987092 PMCID: PMC8111169 DOI: 10.3389/fonc.2021.656918
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Patients’ characteristics of training and validation cohort.
| Characteristic | Training cohort | External Validation cohort |
|---|---|---|
| Patient Number | 69 | 44 |
| Age (years) | ||
| Mean ± standard deviation | 61.1 ± 14.8 | 57.5 ± 15 |
| Sex (male/female) | 41/28 (59.4%/40.6%) | 26/18 (59.1%/40.9%) |
| Tumor type, n (%) | 69 (100%) | 44(100%) |
| Benign | 37 (53.6%) | 24 (38.6%) |
| Pleomorphic adenoma | 18 (26,1%) | 17 (38.6%) |
| Basal cell adenoma | 2 (2.9%) | - |
| Adenomyoepithelioma | 1 (1.5%) | - |
| Myoepithelial | 2 (2.9%) | - |
| Oncocytoma | 1 (1.5%) | - |
| Warthin tumor | 13 (18,8%) | 7 (15.9%) |
| Malignant | 32 (36.4%) | 20 (45.5%) |
| Mucoepidermoid carcinoma | 5 (7.2%) | 3 |
| Acinic cell carcinoma | 2 (2.9%) | 3 |
| Ductal carcinoma | 4 (5.8%) | 3 |
| Adenoidocystic carcinoma | 6 (8.7%) | 4 |
| Lymphoepithelial carcinoma | 3 (4.4%) | 7 others (3 high grade, 1 cystadenocarcinoma, 3 myoepithelial) |
| Carcinoma ex pleomorphic adenoma | 1 (1.5%) | |
| Squamous cell carcinoma | 1 (1.5%) | |
| Metastasis | 10 (14.5%) |
Relevant features included in the predictive models.
| Warthin’s Tumors | Malignant Tumors |
| |||
|---|---|---|---|---|---|
|
|
|
|
| ||
| P25 of ADC (× 10-6 mm2/s) | 911 | 190 | 1058 | 379 | 0.054 |
| Volume Density AEE | 1.29 | 0.07 | 1.26 | 0.10 | 0.011 |
| Benign Tumors | Warthin’s Tumors | ||||
|
|
|
|
|
| |
| P25 of ADC (× 10-6 mm2/s) | 1506.88 | 612.00 | 911.00 | 189.75 | <0.001 |
| Volume Density AEE | 1.26 | 0.07 | 1.29 | 0.07 | 0.0481 |
| Minimum Histogram Gradient | -7.25 | 15.25 | -16.00 | 18.63 | 0.0582 |
| Benign Tumors | Malignant Tumors | ||||
|
|
|
|
|
| |
| P25 of ADC (× 10-6 mm2/s) | 1507 | 612 | 1058 | 379 | <0.001 |
| P10 of T2 | 9.00 | 3.00 | 6.50 | 4.00 | 0.007 |
*P values refer to Mann-Whitney test. P25, 25th percentile of the ADC distribution inside the lesion; P10 of T2, 10th percentile of the T2-weighetd signal intensity distribution inside the lesion; AEE, approximate enclosing ellipsoid.
Predictive Performance of the three models on the training cohort.
| End-point | Selected Features | Accuracy(%) | Sensitivity(%) | Specificity(%) | PPV(%) | NPV(%) |
|---|---|---|---|---|---|---|
|
|
| 86.7 | 87.5 | 84.6 | 93.3 | 73.3 |
|
|
| 91.9 | 84.6 | 95.8 | 91.7 | 92.0 |
|
|
| 80.4 | 84.4 | 75.0 | 81.8 | 78.2 |
*Benign tumors with exclusion of Warthin’s tumors. Abbreviations as in previous tables. In squared brackets the 95% confidence interval is reported.
Predictive Performance of the three models tested on the validation cohort.
| End-point | Selected Features | Accuracy(%) | Sensitivity(%) | Specificity(%) | PPV(%) | NPV(%) |
|---|---|---|---|---|---|---|
|
|
| 81.5 | 90.0 | 57.1 | 85.7 | 66.7 |
|
|
| 91.7 | 85.7 | 94.1 | 85.7 | 94.1 |
|
|
| 89.2 | 85.0 | 94.1 | 94.4 | 84.2 |
*Benign tumors with exclusion of Warthin’s tumors. Abbreviations as in previous tables. In squared brackets the 95% confidence interval is reported.
Chi-square Test performed on qualitative variables, Type of Margins (a) and Type of Contrast Enhancement (b) in the three patient groups.
| a. | ||||
|---|---|---|---|---|
| Type of Enhancement | Homogeneous | Inhomogeneous | Absent | P value |
|
| 0 | 7 | 6 (28.9%) | 0.151 |
|
| 1 | 25 | 6 (71.1%) | |
| (2.2%) | (71.1%) | (26.7%) | ||
|
| 11 | 12 | 1 (64.9%) | 0.001 |
|
| 0 | 7 | 6 (35.1%) | |
| (29.7%) | (51.4%) | (18.9%) | ||
|
| 11 | 12 | 1 (42.9%) | 0.0004 |
|
| 1 | 25 | 6 (57.1%) | |
| (21.4%) | (66.1%) | (12.5%) | ||
Figure 1On the top: three correctly classified lesions in the training dataset: (A) Warthin’s tumor with low T2 intensity, ovoidal shape and decreased ADC value (P25 of ADC = 0.834 × 10-3 mm2/s), (B) pleomorphic adenoma with typical T2 hyperintensity, sharp margins and high ADC value (P25 of ADC is 1.693 × 10-3 mm2/s) (C) malignant tumor with irregular margins, T2 hypointensity and low ADC value, (P25 = 0.744 × 10-3 mm2/s). At the bottom: three misdiagnosed cases in the validation set: (D) Warthin’s tumor with high T2 hyperintensity and irregular shape (P25 of ADC = 0.930 × 10-3 mm2/s); (E) pleomorphic adenoma with no typical T2 intensity and low ADC value (P25 of ADC = 1.109 × 10-3 mm2/s); (F) malignant tumor with typical very low T2 intensity but regular and sharp margin and ovoidal shape (P25 of ADC = 0.836 × 10-3 mm2/s). Each frame illustrates T2-weighted axial image with the user-defined lesion contour on the left and the corresponding ADC map on the right.